Concise review: Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences

Stem Cells

Volumn 30, Issue 3, 2012, Pages 372-378

  Siddique, Hifzur Rahman ^a   Saleem, Mohammad ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

BMI1; Cancer; Cancer recurrence; Cancer stem cells; Chemoresistance

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; BMI1 PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CD44V ANTIGEN; CHECKPOINT KINASE 2; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; GLUTATHIONE; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OKADAIC ACID; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P14; PROTEIN P16; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR SOX2; UVOMORULIN; BMI1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; BLADDER CANCER; BREAST CANCER; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHROMOSOME 10; DNA REPAIR; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; GENE EXPRESSION; GENE LOCATION; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; NASOPHARYNX CARCINOMA; NEURAL STEM CELL; NONHODGKIN LYMPHOMA; OVARY CANCER; PLURIPOTENT STEM CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TH2 CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR RECURRENCE;

MOLONEY MURINE LEUKEMIA VIRUS;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84857497457     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1035     Document Type: Review

References (50)

1. + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106:16281-16286.
2. Cao L, Bombard J, Cintron K et al. BMI1 as a novel target for drug discovery in cancer. J Cell Biochem 2011;112:2729-2741.
3. Crea F, Serrat MAD, Hurt EM et al. BMI1 silencing enhances doce-taxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 2011;128:1946-1954.
4. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-648. (Pubitemid 24067706)
5. Huber GF, Albinger-Hegyi A, Soltermann A et al. Expression patterns of BMI1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer 2011 [Epub ahead of print].
6. Yin T, Wei H, Gou S et al. Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci 2011;12:1595-1604.
7. Raaphorst FM. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 2005;1:R93-R100. (Pubitemid 40542625)
8. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004;113:175-179. (Pubitemid 38544200)
9. Cui H, Hu B, Li T et al. BMI1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007;170:1370-1378. (Pubitemid 47339343)
10. Mihic-Probst D, Kuster A, Kilgus S et al. Consistent expression of the stem cell renewal factor BMI1 in primary and metastatic melanoma. Int J Cancer 2007;121:1764-1770. (Pubitemid 47417295)
11. Balasubramanian S, Lee K, Adhikary G et al. The BMI1 polycomb group gene in skin cancer: Regulation of function by (-)-epigallocate-chin-3-gallate. Nutr Rev 2008;66(suppl 1):S65-S68.
12. Lee K, Adhikary G, Balasubramanian S et al. Expression of BMI1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol 2008;128: 9-17. (Pubitemid 350249374)
13. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423:255-260. (Pubitemid 40852690)
14. Dimri GP, Martinez JL, Jacobs JJ et al. The BMI1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002;62:4736-4745.
15. Hosen N, Yamane T, Muijtjens M et al. BMI1-green fluorescent protein-knock-in mice reveal the dynamic regulation of BMI1 expression in normal and leukemic hematopoietic cells. Stem Cells 2007;25: 1635-1644. (Pubitemid 47121840)
16. Molofsky AV, He S, Bydon M et al. BMI1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005;19:1432-1437. (Pubitemid 41003009)
17. Lukacs RU, Memarzadeh S, Wu H et al. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010;7:682-693.
18. Tian H, Biehs B, Warming S et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011; 478:255-260.
19. Zacharek SJ, Fillmore CM, Lau AN et al. Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell 2011;9:272-281.
20. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokines networks, and the tumor microenvironment. J Clin Invest 2011;121: 3804-3809.
21. Dudley AC, Khan ZA, Shih SC et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008;14:201-211.
22. Clevers H. The cancer stem cell: Premises, promises and challenges. Nature Med 2011;17:313-319.
23. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-4320.
24. Song LB, Zeng MS, Liao WT et al. BMI1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006;66: 6225-6232.
25. Song LB, Li J, Liao WT et al. The polycomb group protein BMI1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009;119:3626-3636.
26. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011;7:517-535.
27. Wiederschain D, Chen L, Johnson B et al. Contribution of polycomb homologues BMI1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol 2007;27:4968-4979. (Pubitemid 47016145)
28. Sangiorgi E, Capecchi MR. BMI1 lineage tracing identifies a self-renewing pancreatic acinar cell subpopulation capable of maintaining pancreatic organ homeostasis. Proc Natl Acad Sci USA 2009;106: 7101-7106.
29. Yang MH, Hsu DS, Wang HW et al. Bmi1 is essential in Twist1- induced epithelial-mesenchymal transition. Nat Cell Biol 2010;12: 982-992.
30. Dong P, Kaneuchi M, Watari H et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011;10:99.
31. Jacobs JJ, Kieboom K, Marino S et al. The oncogene and Polycombgroup gene bmi-1regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-168. (Pubitemid 29050921)
32. Thiery JP, Acloque H, Huang RYJ et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
33. Raimondi C, Gianni W, Cortesi E et al. Cancer stem cells and epithelial-mesenchymal transition: Revisiting minimal residual disease. Curr Cancer Drug Targets 2010;10:496-508.
34. Schmidt CR, Gi YJ, Patel TA et al. E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery 2005;138:306-312. (Pubitemid 41253815)
35. Storci G, Sansone P, Trere D et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008;214:25-37.
36. Jacobs JJ, Scheijen B, Voncken JW et al. BMI1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999;13:2678-2690. (Pubitemid 29508555)
37. Wang E, Bhattacharyya S, Szabolcs A et al. Enhancing chemotherapy response with BMI1 silencing in ovarian cancer. PLoS One 2011;6:e17918.
38. Li J, Gong LY, Song LB et al. Oncoprotein BMI1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol 2010;176:699-709.
39. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521. (Pubitemid 40814659)
40. Hayry V, Tynninen O, Haapasalo HK et al. Stem cell protein BMI1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 2008;34:555-563.
41. Vormittag L, Thurnher D, Geleff S et al. Co-expression of BMI1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int J Radiat Oncol Biol Phys 2009;73:913-918.
42. van Kemenade FJ, Raaphorst FM, Blokzijl T et al. Coexpression of BMI1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001;97:3896-3901.
43. Hayry V, Makinen LK, Atula T et al. BMI1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer 2010; 102:892-897.
44. Vrzalikova K, Skarda J, Ehrmann J et al. Prognostic value of BMI1 oncoprotein expression in NSCLC patients: A tissue microarray study. J Cancer Res Clin Oncol 2008;134:1037-1042.
45. Friedman GK, Gillespie GY. Cancer stem cells and pediatric solid tumors. Cancers 2011;3:298-318.
46. Crea F, Danesi R, Farrar WL. Cancer stem cell epigenetic and chemoresistance. Epigenome 2009;1:63-79.
47. Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and BMI1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-6071.
48. Hosokawa H, Kimura MY, Shinnakasu R et al. Regulation of Th2 cell development by Polycomb group gene BMI1 through the stabilization of Gata-3. J Immunol 2006;177:7656-7664. (Pubitemid 44846280)
49. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006;25:4370-4375. (Pubitemid 44100507)
50. Facchino S, Abdouh M, Bernier G. Brain cancer stem cells: Current status on glioblastoma multiforme. Cancers 2011;3:1777-1797.